Gapping up
In reaction to earnings/guidance:
- WGO +0.6%
Other news:
- TLSA +10% (enters collaboration with FHI clinical to conduct a Phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal Foralumab)
- LOOP +8.9% (entered into ~$56.5 mln Securities Purchase Agreement with SK global chemical Co)
- CDR +4.4% (closes on sale of shopping ctr for $89.7 mln)
- GSK +4% (provides long-term targets for investor update; GSK aims to deliver sales of more than £33 bln by 2031)
- VBIV +3.9% (VBI Vaccines and Brii Biosciences reports completed Phase 1b/2a study on BRII-179)
- PEI +3.8% (Pennsylvania R.E.I.T. highlighted several factors contributing to its optimism about the recovery of its communities)
- CFMS +3.6% (receives exclusive distribution agreement in China)
- SCR +3% (Canada passes bill to allow for single-game wagering)
- NKLA +2.8% (to invest $50 mln in Wabash Valley Resources)
- BGNE +2.1% (receives NMPA approval for Tislelizumab)
- BTBT +2% (Wise Gain Inv discloses 12.28% stake)
- HOLX +1.9% (receives CE Mark for molecular assay to quantify human cytomegalovirus)
- SHAK +1.8% (to open 10 new Shacks in territories in China by 2031)
- CLNE +1.7% (forces conversion of BP's Class B Units into Class A Units relating to joint venture)
- VAL +1.4% (wins contract with North Oil Company offshore Qatar)
- ARWR +1.3% (resented positive interim results from AROHSD1001)
- NTNX +1.2% (names new board chair)
- AZN +1.2% (HUTCHMED and AstraZeneca's (AZN) Orpathys receives approval China)
- DHC +1% (files mixed securities shelf offering)
- MGA +1% (MGA discloses 7.4% stake in FSR related to vested warrants)
- KBR +1% (won a follow-on $58.1 million task order to provide sustainment engineering services for U.S. Air Force systems) .
Analyst comments:
- TH +7.2% (upgraded to Outperform from Perform at Oppenheimer)
- PTEN +2.4% (upgraded to Outperform from In-line at Evercore ISI)
- ACN +2% (upgraded to Outperform from Neutral at Exane BNP Paribas)
- KGC +2% (upgraded to Outperform from Neutral at Credit Suisse)
- URI +1.6% (upgraded to Buy from Neutral at Citigroup)
- PH +1.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)